Corinna Weber-Schoendorfer1, Christof Schaefer. 1. Pharmakovigilanz- und Beratungszentrum Embryonaltoxikologie Berlin, Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Spandauer Damm 130, Haus 10, 14050 Berlin, Germany. weber@embryotox.de
Abstract
OBJECTIVE: To assess the safety of cetirizine during pregnancy. STUDY DESIGN: A prospective observational cohort study with data of the Berlin teratology information center from 1992 until 2006. Pregnancy outcome was compared between a cohort of pregnant women exposed to cetirizine during the first trimester (n=196) and a control group not exposed to potential teratogens (n=1686). RESULTS: Major birth defects were not more common in the study group than in the control group (OR 1.07; CI 0.21-3.59). We also compared the crude rate of spontaneous abortions (OR 0.97; CI 0.54-1.65), of preterm deliveries (OR 0.76; CI 0.35-1.5), and the birth weight of term newborns (p=0.13). CONCLUSIONS: This prospective observational study on cetirizine in pregnancy suggests that the use of cetirizine is relatively safe during the first trimester.
OBJECTIVE: To assess the safety of cetirizine during pregnancy. STUDY DESIGN: A prospective observational cohort study with data of the Berlin teratology information center from 1992 until 2006. Pregnancy outcome was compared between a cohort of pregnant women exposed to cetirizine during the first trimester (n=196) and a control group not exposed to potential teratogens (n=1686). RESULTS: Major birth defects were not more common in the study group than in the control group (OR 1.07; CI 0.21-3.59). We also compared the crude rate of spontaneous abortions (OR 0.97; CI 0.54-1.65), of preterm deliveries (OR 0.76; CI 0.35-1.5), and the birth weight of term newborns (p=0.13). CONCLUSIONS: This prospective observational study on cetirizine in pregnancy suggests that the use of cetirizine is relatively safe during the first trimester.
Authors: Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer Journal: Nat Rev Dis Primers Date: 2022-09-15 Impact factor: 65.038
Authors: Huberdina P M Smedts; Linda de Jonge; Sarah J G Bandola; Marlies E Baardman; Marian K Bakker; Bruno H C Stricker; Régine P M Steegers-Theunissen Journal: Eur J Epidemiol Date: 2014-06-20 Impact factor: 8.082
Authors: Suzanne M Gilboa; Elizabeth C Ailes; Ramona P Rai; Jaynia A Anderson; Margaret A Honein Journal: Expert Opin Drug Saf Date: 2014-10-11 Impact factor: 4.250